Drug Trial Radar · NCT07514338
Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Mar 31, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Pharming Technologies B.V.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Apr 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate if the study medicine, KL1333, is safe, well-tolerated and effective long-term in improving the symptoms of fatigue and impacts on daily living and functional capacity (physical abilities) in people with PMD.
Conditions
- Mitochondrial Diseases
Interventions
NapazimoneDrug
Product: KL1333 (international nonproprietary name: napazimone) Dose: Each subject will be up-titrated to his/her maximum well tolerated dose. The starting dose will be 25 mg KL1333 twice daily (BID; total daily dose of 50 mg). If KL1333 is considered to be well tolerated after 4 weeks of treatment, the dose will be increased to 50 mg KL1333 BID (total daily dose of 100 mg). The dose may be lowered from 50 mg BID to 25 mg BID at the investigator's discretion throughout the study in case of tolerability issues. Frequency: Twice daily Route: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Through study at least for 48 weeks
- Physical examinationTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
- Vital signsTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
- ElectrocardiogramTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
- Safety laboratory - blood chemistryTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
- Safety laboratory - urinalysisTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
- Safety laboratory - hematologyTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
- Occurence of metabolic decompensation and lactic acidosis or image-verified stroke-like episodes consequent to GI AE and AESIsTime frame: Through study at least for 48 weeks
- Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: At Baseline Week 0
Locations
23 sites in 9 countries. Site status is shown where the registry gives one.
Akron Children's Hospital
Akron, Ohio · Recruiting
Hospital Erasme
Brussels, Belgium · Recruiting
Hopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel
Brussels, Belgium · Recruiting
University Hospital
Ghent, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
University Hospital
Leuven, Belgium · Recruiting
Universitair Ziekenhuis Leuven Gasthuisberg Campus
Leuven, Belgium · Recruiting
Charles University and General University Hospital
Prague, Czechia · Recruiting
Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, Denmark · Recruiting
Centre Hospitalier Universitaire d'Angers
Angers, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, France · Recruiting
Hopital Roger Salengro, CHRU de Lille
Lille, France · Recruiting
Centre Hospitalier Universitaire de Nantes
Nantes, France · Recruiting
Centre Hospitalier Universitaire de Nice, Hopital Pasteur 2
Nice, France · Recruiting
CHU de NICE - Hôpital Archet 2
Nice, France · Recruiting
Hopitaux Universitaires de Strasbourg
Strasbourg, France · Recruiting
Universitaetsklinikum Halle
Halle, Germany · Recruiting
Azienda Ospedaliera Universitaria Gaetano Martino Messina
Messina, Italy · Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy · Recruiting
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy · Recruiting
Radboud University Medical Center
Nijmegen, Netherlands · Recruiting
Hospital General Universitario de Catalunya
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.